Mitochondrial

Definition

Mitochondrial peptides are encoded by the mitochondrial genome or designed to act on mitochondrial pathways to enhance energy metabolism, reduce oxidative stress, and modulate cellular aging. This is one of the newest peptide therapeutic categories: most compounds were identified after 2001, when researchers discovered that the mitochondrial genome encodes functional peptides beyond its known tRNA and rRNA genes. The field has grown rapidly, and at least one compound (SS-31) has reached advanced clinical trials.

Mechanism of Action

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino acid mitochondrially-encoded peptide that translocates to the nucleus under metabolic stress. It activates AMPK signaling, modulates the folate cycle, enhances glucose and fatty acid oxidation, and promotes insulin sensitivity. MOTS-c serum levels decline with age, obesity, and insulin resistance — suggesting it as both a biomarker and therapeutic target. Humanin (a 21-amino acid mitochondrially-derived peptide) is anti-apoptotic and neuroprotective, signaling through FPRL1, CNTFR, and interleukin-6 receptor complexes. SS-31 (Elamipretide, d-Arg-Dmt-Lys-Phe-NH2) is a synthetic tetrapeptide that selectively targets cardiolipin in the inner mitochondrial membrane. By protecting cardiolipin from oxidation, it stabilizes mitochondrial cristae architecture, reduces ROS generation, and restores electron transport chain efficiency.

Regulatory Status

SS-31 (Elamipretide, Stealth BioTherapeutics) has received FDA Breakthrough Therapy Designation for Barth syndrome (a rare mitochondrial cardiomyopathy) and has been studied in Phase II trials for primary mitochondrial myopathy. MOTS-c and Humanin are research-stage compounds with no regulatory approval. Research-grade MOTS-c is available through peptide suppliers.

Evidence Base

Elamipretide's Breakthrough Therapy designation signals genuine FDA recognition of therapeutic potential in mitochondrial disease. Phase II/III data in Barth syndrome and primary mitochondrial myopathy show functional improvement and biomarker normalization. MOTS-c has compelling aging biology data in mice — treated aged mice showed improved insulin sensitivity, exercise capacity, and longevity markers. Human aging trial data is early but in progress. Humanin levels in human serum show inverse correlation with age, cardiovascular disease, and Alzheimer's disease — epidemiological associations that support a protective role but do not constitute clinical trial evidence.